Ligand, Proximagen deal

Ligand transferred to Proximagen exclusive, worldwide rights to develop and commercialize undisclosed compounds targeting the CXC chemokine receptor 4 ( CXCR4; NPY3R). The compounds are in preclinical development to treat CNS diseases. Ligand received $250,000 up front and is eligible for undisclosed milestones and royalties. ...